ライフサイエンスコーパス: class II antigen

1 T cells or major histocompatibility complex class II antigen.

2 EPC, neonatal knockout EPC expressed little class II antigen.

3 I and major histocompatibility complex (MHC) class II antigens.

4 elial expression of major histocompatibility class II antigens.

5 ed by the complete lack of expression of MHC class II antigens.

6 peptides in the context of both class I and class II antigens.

7 ion of donor-specific antibodies against MHC class II antigens.

8 orst when the donor and recipient shared MHC class II antigens.

9 nts can develop anti-HLA antibodies to donor class II antigens.

10 essed major histocompatibility complex (MHC) class II antigens.

11 ree cases, antibodies were against donor HLA class II antigens.

12 are being activated by mismatched donor HLA-class II antigens.

13 All aspirates were negative for MHC class II antigens.

14 cted at major histocompatibility class (MHC) class II antigens.

15 d expression of FCgammaRI, CR3, CR4, and MHC class II antigens.

16 heat shock cognate 70; histocompatibility 2, class II antigen A, alpha; and the T cell cytokine recep

17 We disrupted the histocompatibility 2, class II antigen A, beta 1 gene (H2-Ab1) in IECs of C57B

18 0), and DQ8.Ab(0), lacking their own (mouse) class II antigens (Ab(0)), on the original (arthritis-re

19 ass II(-) but that are capable of expressing class II antigen after surgery and migrating to draining

20 nt in major histocompatibility complex (MHC) class II antigen (Ag)-T-cell receptor (TCR), B7-CD28, or

21 cell major histocompatibility complex (MHC) class II antigen and for gamma-interferon (gamma-IFN), i

22 he minimal truncated form that binds the MHC Class II antigen and triggers superoxide production thro

23 s in the cell surface expression of both MHC class II antigens and IL-4 receptor are completely abrog

24 Intestinal epithelial cells can express HLA class II antigens and may function as antigen-presenting

25 nalysis demonstrated eight were specific for class II antigens and one for class I antigens.

26 nizing donor antigens presented by recipient class II antigens, and (2) CD8+ cells can participate as

27 HLA class I antigens, 56% developed against class II antigens, and 12% developed against both.

28 ce lacking the cytoplasmic tail of their MHC class II antigens, and mice depleted of CD4+ cells by an

29 nt; almost all de novo DSAs were against HLA class II antigens, and the majority were against DQ anti

30 phase matrix to which soluble HLA class I or class II antigens are attached is significantly more sen

31 se of the disease since both HLA class I and class II antigens are critical to the interaction betwee

32 Thus, MHC class II antigens are essential for the expression of au

33 major histocompatibility complex class I and class II antigens as well as the costimulatory molecules

34 h expressed major histocompatibility complex class II antigen; B cells and exogenous monocytes/macrop

35 ndosomes/lysosomes, possibly after or before class II antigen binding.

36 l hydrogen bonds at the opposite ends of the class II antigen-binding groove (beta-His-81, beta-Asn-8

37 of peptide residues projecting from the MHC class II antigen-binding groove as part of a mini beta s

38 on of the Ii-derived (CLIP) peptide from the class II antigen-binding pocket and subsequent peptide l

39 and canine major histocompatibility complex class II antigens but is reactive with a narrower spectr

40 ng of major histocompatibility complex (MHC) class II antigens by anti-HLA-DR monoclonal antibody (Mo

41 onor class II antigens or modified recipient class II antigens; (c) isotype switching from IgM to IgG

42 esses major histocompatibility complex (MHC) class II antigens constitutively.

43 tion of donor peptides presented by host MHC class II antigens contributes to transplant rejection in

44 In previous studies, absence of donor MHC class II antigens did not affect skin graft survival, bu

45 Absence of donor MHC class II antigens did not affect the production of eithe

46 rminants, CD138 and major histocompatibility class II antigens, distinguish developing B-1 cells from

47 patients, with the majority directed at HLA class II antigens (DR, 41%; DQ, 53%).

48 HLA class II antigens, DR, DQ, and DP, comprised an alpha an

49 nduced pulmonary fibrosis and identified MHC class II antigen Ealpha (H2-Ea) as a risk factor for thi

50 ein (GFAP) and (3) staining for OX-6, an MHC class II antigen expressed by microglia and macrophages.

51 from horses with uveitis had clusters of MHC class II antigen-expressing cells, T lymphocytes, and en

52 s of scid mice with evidence of enhanced MHC class II antigen expression and increased phagocytosis (

53 his study determines the effect of E2 on MHC class II antigen expression in the allograft, in the abs

54 associated with inhibition of inducible MHC class II antigen expression in the allografts.

55 estradiol-17beta abolition of inducible MHC class II antigen expression in the aorta allograft occur

56 f cardiac allograft recipients abolishes MHC class II antigen expression in the coronary arteries and

57 E2 treatment, we observed that inducible MHC class II antigen expression is abolished in the media of

58 We have observed high constitutive levels of class II antigen expression on porcine and human coronar

59 by 2-5 d; the associated upregulation of MHC class II antigen expression suggested increased immunoge

60 gulation of major histocompatibility complex class II antigen expression was also noted.

61 MHC class II antigen expression was not detectable in allogr

62 (H&E, collagen) and immunohistochemical (MHC class II antigen expression, infiltration of T and B lym

63 on of major histocompatibility complex (MHC) class II antigen expression, T lymphocytes, and macropha

64 gulation of major histocompatibility complex class II antigen expression.

65 gans associated with the upregulation of MHC class II antigen expression.

66 genic C57BL/6 mouse strains differing in MHC class II antigen expression.

67 essed major histocompatibility complex (MHC) class II antigens for at least 48 h in vitro.

68 oid A family, three major histocompatibility class II antigen genes, and various cytokine-related gen

69 pression of major histocompatibility complex class II antigens (>75%), interleukin (IL) 2 receptor (5

70 These studies indicate that the MHC class II antigen haplotype controls myocarditis suscepti

71 and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesi

72 taining the major histocompatibility complex class II antigen, HLA-DR.

73 Absence of recipient MHC class II antigens, however, led to production of only Ig

74 the murine major histocompatibility complex class II antigen I-Ak expressed on M12.C3.F6 cells has 1

75 Th2 (IL-4+) cell response, express both MHC class II antigens (IA(d), IE(d)) and are atherosclerosis

76 r levels of major histocompatibility complex class II antigens (IEk) than spleen DCs.

77 pecific for major histocompatibility complex class II antigens) immunolabeling and Arc fluorescence i

78 SLA class I and the induction of SLA class II antigen in response to interferon-gamma treatme

79 with COVID-19 (55%) and upregulation of MHC class II antigens in 7 of 42 specimens from patients wit

80 e of rodent species, express basal levels of class II antigens in a manner similar to that observed i

81 show that the effector T cells recognize MHC class II antigens in association with a peptide from the

82 pression of major histocompatibility complex class II antigens in F4/80(+) and CD11b+ spleen cells.

83 The role of major histocompatibility complex class II antigens in hematopoiesis is not well defined.

84 To further explore the role of MHC class II antigens in kidney graft rejection, we performe

85 s and suggest that the additional absence of class II antigens in TGF-beta1(-/-);MHC-II(-/-) mice may

86 ecules, and major histocompatibility complex class II antigens in the engrafted organ.

87 These results support a role of MHC class II antigens in the kidney regulating immune cells

88 Upregulation of major histocompatibility class II antigens increased organ immunogenicity.

89 Prior sensitization against HLA class II antigens is associated with unfavorable long-te

90 renal allograft rejection, expression of MHC class II antigens is up-regulated on the parenchymal cel

91 ells, and the Abs tested were antimature MHC class II antigen (lacking the invariant chain) and anti-

92 the cytoplasmic tail of the recipient's MHC class II antigens led to the production of slightly redu

93 also were located in the compartment for MHC class II antigen loading (MIIC).

94 Second, they show features of MHC class II antigen-loading competent compartments for cath

95 al markers (major histocompatibility complex class II antigen, macrophage, and CD4- and CD8-positive

96 and for immunohistochemical staining of MHC class II antigens, macrophages, CD4 and CD8 T lymphocyte

97 Overall, class II antigen mismatches were associated with more re

98 the mean number of mismatches for Class I or Class II antigens, nor could any Class I/II phenotype fo

99 bility was observed in the expression of HLA class II antigens, not only between individuals but also

100 xpression of costimulatory molecules and MHC class II antigen on DCs isolated from livers of FL-treat

101 antibodies against allogeneic MHC class I or class II antigens on the development of early high-grade

102 histocompatibility complex (MHC) class I and class II antigens on the sarcolemma, and a blinded evalu

103 histocompatibility complex (MHC) class I and class II antigens on their surface and to interact with

104 l CD4+ cell population (due to expression of class II antigens only on thymic epithelium), mice lacki

105 r histocompatibility complex class I but not class II antigens or B7 costimulatory molecules.

106 rom CD4+ cells, which recognize either donor class II antigens or modified recipient class II antigen

107 ance of antibodies directed against some HLA class II antigens, particularly HLA-DP, is less clear wi

108 The possibility that MIF participates in class II antigen presentation and/or as a chaperone is d

109 s expression of the major histocompatibility class II antigen presentation apparatus, via secreted IL

110 cal pathways for DNA-mismatch repair and MHC class II antigen presentation are consistently associate

111 y classical major histocompatibility complex class II antigen presentation but also nonclassical CD1d

112 pression of major histocompatibility complex class II antigen presentation genes in bone marrow disce

113 So far, most prediction methods for HLA class II antigen presentation have focused on HLA-DR bec

114 In addition to showing deficient MHC class II antigen presentation in a subset of HRS cells,

115 Recent progress in the study of class II antigen presentation includes the identificatio

116 on of major histocompatibility complex (MHC) class II antigen presentation is believed to be among th

117 Induction of the MHC class II antigen presentation machinery by cotransfectin

118 a-cells also expressed mRNA for Class II and Class II antigen presentation pathway components, but la

119 adation of two essential proteins in the MHC class II antigen presentation pathway: HLA-DR-alpha and

120 histocompatibility complex (MHC) class I and class II antigen presentation pathways, functioning in c

121 he increased efficacy of MHC class I and MHC class II antigen presentation relative to a control scFv

122 between glycation reactions and altered MHC class II antigen presentation that may contribute to T2D

123 ed markedly differing dependence on host MHC class II antigen presentation, depending on the donor sp

124 of ICP34.5 in precluding autophagy-mediated class II antigen presentation, thereby enhancing the vir

125 in in vivo to improved DC activation and MHC class II antigen presentation.

126 w of the ins and outs of MHC class I and MHC class II antigen presentation.

127 intracellular degradation pathway, regulates class II antigen presentation.

128 s enriched for type II IFN signaling and MHC-class II antigen presentation.

129 dings complete the structural path governing class II antigen presentation.

130 regulatory module that programs enhanced MHC class II antigen presentation.

131 skewing, T cell receptor signaling, and MHC class II antigen presentation.

132 may disrupt major histocompatibility complex class II antigen presentation.

133 nced activity of the classic MHC class I and class II antigen-presentation pathways.

134 ressing the major histocompatibility complex class II antigen-presenting cell function of macrophages

135 ivation and to provide signals back into the class II antigen-presenting cell.

136 ophages and major histocompatibility complex class II antigen-presenting cells in the bone resorption

137 ly endosomes and proper sorting into the MHC class II antigen-presenting compartment (MIIC).

138 rotein that impairs both the MHC class I and class II antigen-presenting pathways.

139 at line the peptide-binding pockets of HLA's Class II antigen-presenting proteins is superimposed on

140 ead, recall Th1 response was elicited by MHC class II(+) antigen-presenting cells at the site of infe

141 ed by other major histocompatibility complex class II(+) antigen-presenting cells.

142 s observed in these chimeras, as long as rat class II+ antigen-presenting cells remain in their thymi

143 iant chain (Ii) plays a critical role in MHC class II antigen processing by stabilizing peptide-free

144 ge of major histocompatibility complex (MHC) class II antigen processing enzymes in order to evade or

145 gest the use of two distinct pathways of HLA class II antigen processing in enterocytes with differen

146 h the major histocompatibility complex (MHC) class II antigen processing pathway can be recognized by

147 ined through a molecular analysis of the HLA class II antigen processing pathway.

148 In an attempt to enhance MHC class II antigen processing, we linked the sorting signa

149 but not by an inhibitor (chloroquine) of MHC class II antigen processing.

150 onse, MHC (Major Histocompatibility Complex) class II, antigen processing and presentation, allograft

151 plex class II molecule, HLA-DO, inhibits the class II antigen-processing pathway.

152 Further, effector pathways triggered by class II antigens promote renal injury during rejection.

153 red to collectively as IDDM1), including the class II antigen receptor genes, which control the major

154 restricted CD8(+) T cells with help from MHC class II antigen-restricted CD4(+) T lymphocytes.

155 ds coated with human leukocyte antigen (HLA) class II antigens showed no class II antibodies in sera

156 on of major histocompatibility complex (MHC) class II antigen-specific CD4(+) T cell responses in DCs

157 Although activated human T cells express MHC class II antigens, the regulation of these antigens in T

158 y trigger an autoimmune reaction against MHC class II antigens through mimicry.

159 an adult pattern, but failed to up-regulate class II antigen to the high level seen among cultured a

160 enase interacts with diabetes-associated MHC class II antigens to limit T-cell activation.

161 The contribution of MHC class II antigens to the genesis of this phenotype has b

162 order, but without narcolepsy, underwent HLA class II antigen typing: 84% (N=21) were DQwl (DQB1*05,0

163 mice whose major histocompatibility complex class II antigen was replaced with the human leukocyte a

164 with enhanced expression of HLA class I and class II antigens was detected in FP-cultured DCs as com

165 Antibodies against 96 class I and 76 class II antigens were investigated and patients had a m

166 Antibodies to donor class II antigens were slightly more common, occurring i

167 vagina, but major histocompatibility complex class II antigens were still partially upregulated in th

168 red mice that did not express MHC class I or class II antigens were used to study the allorecognition

169 presses increased amounts of MHC class I and class II antigens when transplanted to SCID mice.